Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad
More articles/Ad
More articles
-
An end-of-year surge in deal-making has sparked predictions of a boom in leveraged buy-outs -
Italian pharmacy group to refinance €460m of debt and pursue acquisitions
-
Bumpy ride ahead but investors see emerging markets as big beneficiaries
-
Top tier name profits from its track record to pay lower upfront costs
-
EQT is waiting for the right valuation for the Swiss skincare company
-
Investors piled into trades ahead of the Thanksgiving shutdown
